kaftrio(Trikafta)的用法用量:用药指南,剂量调整,特殊人群用药,用药注意事项
It is very important to know the correct usage and dosage of medicines. This article will introduce in detail the usage and dosage of kaftrio (Trikafta), as well as dosage adjustments, to help you use the medication rationally.
1. Adult dosage
kaftrio (Trikafta) needs to be taken once a day in the morning and evening. The following is the specific dosage instructions for morning and evening dosage:
Morning dose
Take orally 2 tablets (containing elecarpol 100mg/tezakafor 50mg/ivacaftor 75mg) once in the morning.
Evening dose
Take 1 tablet (containing ivacaftor 150mg) orally once in the evening.
2. Medication Notes
Gene Testing
If the genotype is unknown, it is necessary to confirm that the patient carries at least one F508del mutation or a responsive mutation supported by in vitro data through FDA-approved cystic fibrosis (CF) mutation testing.
Length of dosing interval
The interval between two doses should be approximately 12 hours.
Precautions for taking together
kaftrio (Trikafta) should be taken with fatty foods.
2. Children's dosage
1. 2 years old to <6 years old
2 years old to <6 years old, weight <14kg
Take orally 1 packet of granules (containing 80 mg of elecarpol/40 mg of terzacafort/60 mg of ivacaftor) once in the morning.
Take 1 packet of granules (containing ivacaftor 59.5mg) orally once in the evening.
2 years old to <6 years old, weight ≥14kg
Take orally 1 packet of granules (containing elecarpol 100mg/tezakafor 50mg/ivacaftor 75mg) once in the morning.
Take 1 packet of granules (containing ivacaftor 75mg) orally once in the evening.
2. 6 years old to <12 years old
6 years old to <12 years old, weight <30kg
Take orally 2 tablets (containing elecarpol 50mg/Terzacafort 25mg/Ivacaftor 37.5mg) once in the morning.
Take 1 tablet (containing ivacaftor 75mg) orally once in the evening.
6 to <12 years old, weight ≥30kg
Take orally 2 tablets (containing elecarpol 100mg/tezakafor 50mg/ivacaftor 75mg) once in the morning.
Take 1 tablet (containing ivacaftor 150mg) orally once in the evening.
3. ≥12 years old
Same as adult dosage regimen.
4. Medication precautions
Gene testing
If the genotype is unknown, it is necessary to confirm that the patient carries at least one F508del mutation or a responsive mutation supported by in vitro data through FDA-approved cystic fibrosis (CF) mutation testing.
Dosing interval
The interval between two doses of kaftrio (Trikafta) is about 12 hours.
Notes on the same server
kaftrio (Trikafta) granules need to be mixed with soft food or liquid before taking.
3. Dose adjustment
1. Renal function adjustment
Mild to moderate renal insufficiency (CrCl≥30mL/min/1.73m²): No dose adjustment is required.
Severe renal insufficiency (CrCl<30mL/min/1.73m²) or end-stage renal disease (ESRD): Use with caution (data limited).
2. Liver function adjustment
Mild liver injury (Child-Pugh A grade): No adjustment required.
Moderate hepatic impairment (Child-Pugh Class B): Use with caution.
3. 2 years old to <6 years old
(1) 2 years old to <6 years old, weight <14kg
Days 1-3: Take 1 packet of granules (elacapor 80mg/tezakafor 40mg/ivacaftor 60mg) orally in the morning.
Day 4: Stop taking medication.
Day 5-6: Take 1 packet of granules orally in the morning.
Day 7: Stop taking medication.
Cycle this weekly regimen, and do not take evening ivacaftor granules every day.
(2) 2 years old to <6 years old, weight ≥14kg
Same plan, switch to granules containing elecarpol 100mg/tezakafort 50mg/ivacaftor 75mg.
4. 6 years old to <12 years old
(1) 6 years old to <12 years old, weight <30kg
Day 1: Orally take 2 tablets in the morning (elicapol 50mg/Tezakafor 25mg/Ivacaftor 37.5mg).
Day 2: Orally take 1 tablet (same ingredients as above) in the morning.
Cycle this alternating regimen, and daily evening ivacaftor tablets are prohibited.
(2) 6 years old to <12 years old, weight ≥30kg
Same plan, but use tablets containing elecarpol 100mg/tezakafort 50mg/ivacaftor 75mg.
Warm reminder
Patients with moderate liver damage should only use it when their medical needs are clear and the benefits outweigh the risks, and liver function needs to be closely monitored.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)